Online citations, reference lists, and bibliographies.
← Back to Search

Quinazolin‐4(3H)‐one‐Based Hydroxamic Acids: Design, Synthesis And Evaluation Of Histone Deacetylase Inhibitory Effects And Cytotoxicity

Doan Thanh Hieu, D. T. Anh, Pham-The Hai, N. T. Thuan, Le‐Thi‐Thu Huong, E. J. Park, A. Young Ji, Jong Soon Kang, Phan Thi Phuong Dung, S. Han, N. Nam
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The present article describes the synthesis and biological activity of various series of novel hydroxamic acids incorporating quinazolin‐4(3H)‐ones as novel small molecules targeting histone deacetylases. Biological evaluation showed that these hydroxamic acids were potently cytotoxic against three human cancer cell lines (SW620, colon; PC‐3, prostate; NCI−H23, lung). Most compounds displayed superior cytotoxicity than SAHA (suberoylanilide hydroxamic acid, Vorinostat) in term of cytotoxicity. Especially, N‐hydroxy‐7‐(7‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)heptanamide (5b) and N‐hydroxy‐7‐(6‐methyl‐4‐oxoquinazolin‐3(4H)‐yl)heptanamide (5c) (IC50 values, 0.10–0.16 μm) were found to be approximately 30‐fold more cytotoxic than SAHA (IC50 values of 3.29–3.67 μm). N‐Hydroxy‐7‐(4‐oxoquinazolin‐3(4H)‐yl)heptanamide (5a; IC50 values of 0.21–0.38 μm) was approximately 10‐ to 15‐fold more potent than SAHA in cytotoxicity assay. These compounds also showed comparable HDAC inhibition potency with IC50 values in sub‐micromolar ranges. Molecular docking experiments indicated that most compounds, as represented by 5b and 5c, strictly bound to HDAC2 at the active binding site with binding affinities much higher than that of SAHA.
This paper references
10.1093/JNCI/82.13.1107
New colorimetric cytotoxicity assay for anticancer-drug screening.
Philip Skehan (1990)
10.1093/JNCI/92.15.1210
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
P. Marks (2000)
10.1002/PTR.901
Antiinvasive, antiangiogenic and antitumour activity of Ephedra sinica extract
N. Nam (2003)
10.1042/BJ20021321
Histone deacetylases (HDACs): characterization of the classical HDAC family.
Annemieke J M de Ruijter (2003)
10.2174/1389450033346966
Current targets for anticancer drug discovery.
N. Nam (2003)
10.1016/S0960-894X(03)00558-4
Antitumor activity of unsaturated fatty acid esters of 4'-demethyldeoxypodophyllotoxin.
Young-Jae You (2003)
10.1038/nrd2133
Anticancer activities of histone deacetylase inhibitors
J. E. Bolden (2006)
10.1038/sj.cr.7310149
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics
P. Gallinari (2007)
10.1016/J.BCP.2007.04.007
HDAC inhibitors: clinical update and mechanism-based potential.
K. Glaser (2007)
10.1186/1476-4598-7-70
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells
Marielle Dejligbjerg (2007)
10.1021/JM070416O
Synthesis and evaluation of tripodal peptide analogues for cellular delivery of phosphopeptides.
Guofeng Ye (2007)
10.1111/j.1582-4934.2011.01321.x
Class IIa HDACs: from important roles in differentiation to possible implications in tumourigenesis
Andrea Clocchiatti (2011)
10.1016/j.bmcl.2011.07.124
Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
D. K. Oanh (2011)
10.1021/ja111104p
Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel.
Ruibo Wu (2011)
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review
S Valente (2011)
10.1007/s12272-012-0221-9
Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery
Seung-Yong Seo (2012)
10.1007/978-3-642-38111-9_5
Hydroxamic Acids as Histone Deacetylase Inhibitors
F. Thaler (2013)
10.1074/jbc.M113.490706
Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
B. Lauffer (2013)
10.2217/fon.12.173
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Tianzhu Qiu (2013)
10.2147/BTT.S29965
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
K. Ververis (2013)
10.1016/j.ejmech.2013.10.045
Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Nguyen-Hai Nam (2013)
10.2174/15734064113099990027
New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
T. T. Tung (2013)
Nguyen-Hai, ‘New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents
T. T. Tung (2013)
10.2174/09298673113209990191
A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity.
H. Rajak (2014)
10.3109/14756366.2013.832238
Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents
Nguyen-Hai Nam (2014)
10.1517/13543776.2014.877446
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)
S. Valente (2014)
10.2174/1573406411666150702130633
Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
D. T. Dung (2015)
10.1517/17460441.2015.1038236
Emerging approaches for histone deacetylase inhibitor drug discovery
C. Zwergel (2015)
10.2174/1573406410666140925153128
5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
Trần Thị Lan Hương (2015)
10.3390/molecules20033898
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Madhusoodanan Mottamal (2015)
10.1038/nrd4583
HDAC inhibitors still need a home run, despite recent approval
M. Guha (2015)
Nguyen-Hai, ‘5-Aryl-1,3,4-thiadiazolebased hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study
T. L. Huong (2015)
One-way ANOVA followed by Dunnett's multiple comparisons test was performed using GraphPad Prism version 7.00 for Windows, GraphPad Software
(2015)
4-thiadiazolebased hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study
T L Huong (2015)
Nguyen-Hai, ‘Novel 3-substituted-2-oxoindolinebased N-hydroxypropenamides as Histone Deacetylase Inhibitors and Antitumor Agents
T.M.D. Do (2015)
Discovery Studio Modeling Environment
Dassault Systèmes (2016)
10.1016/j.bioorg.2017.02.002
Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
T. Huong (2017)
10.1007/s11696-017-0172-1
Exploration of some indole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents
Trần Thị Lan Hương (2017)
10.1080/1062936X.2017.1294198
Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries
H. Pham-The (2017)
10.2174/1568026618666171212111018
Learning from Multiple Classifier Systems: Perspectives for Improving Decision Making of QSAR Models in Medicinal Chemistry.
H. Pham-The (2018)
10.2174/1573406414666180528111749
Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
D. T. Dung (2018)
10.1002/cbdv.201800027
Quinazoline‐Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity
D. Hieu (2018)
Design, synthesis and evaluation of novel Nhydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents
D. T. Hieu (2018)
10.1093/bioinformatics/bty707
admetSAR 2.0: web‐service for prediction and optimization of chemical ADMET properties
H. Yang (2019)
H-7a, H-7b), 2.60 (3H, s, 2'-Me)
Mhz
6-Dimethyl-4-oxoquinazolin-3(4H)-yl)-N-hydroxyheptanamide (10b). White solid. Yield: 64 %
DMSO): 10.35 (1H, s, NH), 8.68 (1H, s, OH), 7.86 (1H, s, H-5'), 7.71 (2H, s, H-7', H-8'), 4.50 (2H, s, H-7a, H-7b), 2.59 (3H, s, 2'-Me), 2.51 (3H, s, 6'-Me), 1.97 (2H, t, J = 7.25, H-2a, H-2b



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar